Senior Downstream Process Development Scientist
Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and infectious diseases with a high unmet medical need. With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses. Our vision is to build a leading vaccine technology biotech company developing game changing medicine across an expanding range of therapeutic areas. In our mission to bring our discoveries to the people who need them, we are proud to collaborate with world-class organizations. In oncology, our partners are Roche, Genentech, and Nektar Therapeutics. We have a multi-target collaboration with Regeneron within oncology and infectious diseases. For COVID-19 vaccine development, we have a strong relationship with Adaptive Biotechnologies.
Lytix Biopharma is hiring a CMC manager
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.
Cepheid søker Business Development Manager
At Cepheid, we are passionate about improving health care through fast, accurate diagnostic testing. Our mission drives us, every moment of every day, as we develop scalable, groundbreaking solutions to solve the world’s most complex health challenges. Our associates are involved in every stage of molecular diagnostics, from ideation to development and delivery of testing advancements that improve patient outcomes across a range of settings. As a member of our team, you can make an immediate, measurable impact on a global scale, within an environment that fosters career growth and development. Cepheid is proud to work alongside a community of six fellow Danaher Diagnostics companies. Together, we’re working at the pace of change on diagnostic tools that address the world’s biggest health challenges, driven by knowing that behind every test there is a patient waiting.
Early stage Biotech searching a Product Engineering and Development Lead
We are a stealth early stage biotech with multiple locations, including Oslo, Basel, and soon Cambridge (USA) - the name will change shortly! Our mission is to develop therapeutics that extend patients' lives and also improve their quality of life. We specialize in developing targeted radioligand therapeutics and we are growing our new company with roots in the Oslo ecosystem of radiobiology, and founders with a track record of developing new therapies. We are backed by international venture capital groups with deep scientific roots who understand what it takes to develop and scale a technology to deliver new therapies.
Scientist in Technology Development
At Bayer we always start by listening – because our customers are at the heart of everything we do. The needs of our customers and the challenges facing society inspire us to develop ideas that improve people’s lives. As part of the Bayer team, each of us needs to thoroughly understand and support our customers in order to deliver products and solutions that matter – now and in the future Bayer Nordic is our regional organization for Northern Europe. You find us in Finland, Denmark, Norway, Sweden, Iceland and the Baltic countries, i.e. Estonia, Latvia and Lithuania. We are more than 1500 people who are passionate to make a difference. In the Nordic region we have two global R&D and production sites, in Finland and Norway. The Turku-based production facility is one of the Group's global pharmaceutical production facilities, where medicines are manufactured in more than 130 countries. Over the last years Bayer has increased its investments, research activities and partnerships in the Nordics, and we are proud of being one of the most significant Life Science companies in the region. Why Bayer? Because we’re a pioneer in the fields of human and plant health. Because we invent the solutions that will create a sustainable future for our planet. Because a career with Bayer means you can put your passion into practice and make an impact.
Bayer Norway is seeking Laboratory Technician
At Bayer we always start by listening – because our customers are at the heart of everything we do. The needs of our customers and the challenges facing society inspire us to develop ideas that improve people’s lives. As part of the Bayer team, each of us needs to thoroughly understand and support our customers in order to deliver products and solutions that matter – now and in the future Bayer Nordic is our regional organization for Northern Europe. You find us in Finland, Denmark, Norway, Sweden, Iceland and the Baltic countries, i.e. Estonia, Latvia and Lithuania. We are more than 1500 people who are passionate to make a difference. In the Nordic region we have two global R&D and production sites, in Finland and Norway. The Turku-based production facility is one of the Group's global pharmaceutical production facilities, where medicines are manufactured in more than 130 countries. Over the last years Bayer has increased its investments, research activities and partnerships in the Nordics, and we are proud of being one of the most significant Life Science companies in the region. Why Bayer? Because we’re a pioneer in the fields of human and plant health. Because we invent the solutions that will create a sustainable future for our planet. Because a career with Bayer means you can put your passion into practice and make an impact.
Hubro Therapeutics is seeking QA Manager / QA Sr Manager
Hubro Therapeutics AS is a clinical stage private Norwegian biotech company founded in 2018 and located in Oslo. Our focus is on development of novel proprietary anti-cancer vaccines. We believe that cancer vaccines will play important roles for the further improvement of immunotherapy of cancer. It is our desire and sincere hope to improve the lives of cancer patients. Our lead candidate peptide vaccine in clinical development is FMPV-1. FMPV-1 targets frameshift mutation in the transforming growth factor β receptor 2 (TGFβR2) gene, frequently present in MSI-colorectal, stomach cancer as well as in hereditary colorectal cancer. We have two new vaccine candidates in our pipeline ready for the initiation of clinical development. More info at www.hubrotherapeutics.com
CMC Director and CMC Sr. Manager to Hubro Therapeutics
Hubro Therapeutics AS is a clinical stage private Norwegian biotech company founded in 2018 and located in Oslo. Our focus is on development of novel proprietary anti-cancer vaccines. We believe that cancer vaccines will play important roles for the further improvement of immunotherapy of cancer. It is our desire and sincere hope to improve the lives of cancer patients. Our lead candidate peptide vaccine in clinical development is FMPV-1. FMPV-1 targets frameshift mutation in the transforming growth factor β receptor 2 (TGFβR2) gene, frequently present in MSI-colorectal, stomach cancer as well as in hereditary colorectal cancer. We have two new vaccine candidates in our pipeline ready for the initiation of clinical development.
Produktsjef (legemiddelbransjen)
Fresenius Kabi er et globalt selskap som har spesialisert seg på legemidler og teknologi for infusjon, transfusjon og klinisk ernæring. Våre produkter og tjenester brukes i behandlingen av kronisk syke og kritisk syke pasienter. Vår fabrikk i Halden produserer vannbaserte legemidler til infusjon, injeksjon, skylling og desinfeksjon i plastemballasje. Vi leverer også spesialblandinger til norske sykehus, i første rekke parenteral ernæring og produkter for smertebehandling. Vårt salgs- og markedsføringsselskap med 25 ansatte er lokalisert Nydalen i Oslo. Vi er et bredt sammensatt team og har til sammen en bred faglig kompetanse. Våre oppgaver er å markedsføre og selge vår produktportefølje gjennom anbudsbesvarelser og forhandlinger. Vi besvarer kundehenvendelser, utarbeider brosjyrer og annet støttemateriell for bruk av produktene våre, håndterer reklamasjoner og bivirkningsmeldinger, og støtter våre kunder på deres arbeidssted med kurs, opplæring og informasjon
Key Account Manager
GSK er et globalt forskningsdrevet biofarmasøytisk selskap. GSKs mål er å forene vitenskap, teknologi og talent, slik at vi sammen kan være i forkant av sykdomsutviklingen. Vi tilbyr et bredt spekter av vaksiner og legemidler, både til bruk innen spesialist- og primærhelsetjenesten. Vår forskning og utvikling er fokusert på immunforsvaret, genetikk og avansert teknologi innen fire hovedområder; infeksjonssykdommer, hiv, onkologi og lungesykdommer. I GSK Norge er vi ca. 60 personer, og vi holder til på Lysaker. Vi jobber med alt fra medisinske prosjekter til markedstilgang/helseøkonomi, markedsføring, salg og ulike støttefunksjoner - alt for å sørge for at norske pasienter og samfunnet kan ta i bruk nye medisiner og vaksiner.
Bayer is looking for a Head of CMC Documentation Alpha-Pharmaceuticals
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result, we are investing heavily in production and R&D in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 50-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
Laboratory IT Professional
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result, we are investing heavily in production and R&D in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 50-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
Bayer is seeking Head of Technology Development
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result, we are investing heavily in production and R&D in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 50-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
QA Direktør søkes til IFE Divisjon Radiofarmasi
Divisjon Radiofarmasi er en del av IFE (Institutt for Energiteknikk) og holder til på Kjeller. Divisjonen har en verdensledende produksjonsvirksomhet innen radioaktive legemidler og skal ved årsskiftet 2022/23 skilles ut og etableres som et eget AS. Med norske og multinasjonale samarbeidspartnere utvikles, produseres og distribueres banebrytende legemidler for kreftpasienter over hele verden. Divisjonen er i dag om lag 150 medarbeidere i virksomheten, med en omsetning på ca. 360 mill. kr
NorthSea Therapeutics seeking Project Manager
NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. NST licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS, who developed Lovaza® (US brand, branded Omacor® in Europe), a blockbuster cardiovascular drug. Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA-1024 is in phase 1 to be developed for dyslipidemia, and SEFA-6179, entered phase 1 in December 2021, is being developed for the orphan indication IFALD, (Intestinal Failure Associated Liver Disease). NST is headquartered in the Netherlands with a presence in Norway and the US and is supported by Ysios Capital, Forbion Growth, Hercules Capital, Forbion Ventures, Novo Seeds, BGV, NSV, venBio Partners and Sofinnova investments.
GSK søker Nasjonal Salgssjef
GSK er et globalt forskningsdrevet biofarmasøytisk selskap. GSKs mål er å forene vitenskap, teknologi og talent, slik at vi sammen kan være i forkant av sykdomsutviklingen. Vi tilbyr et bredt spekter av vaksiner og legemidler, både til bruk innen spesialist- og primærhelsetjenesten. Vår forskning og utvikling er fokusert på immunforsvaret, genetikk og avansert teknologi innen fire hovedområder; infeksjonssykdommer, hiv, onkologi og lungesykdommer. I GSK Norge er vi ca. 60 personer, og vi holder til på Lysaker. Vi jobber med alt fra medisinske prosjekter til markedstilgang/helseøkonomi, markedsføring, salg og ulike støttefunksjoner - alt for å sørge for at norske pasienter og samfunnet kan ta i bruk nye medisiner og vaksiner.
FMGC – legemidler – business development
Santen er et av verdens ledende foretak innen øyeforskning. Santen ble etablert i Japan i 1890 og er i dag en av verdens største produsenter av legemidler innen behandling av øyesykdommer og forbedring av menneskers syn. Vi er overbevist om at bedre syn også gir en høyere livskvalitet. Derfor har vi i Santen satt øyet og synsevnen i sentrum for hele vår virksomhet som legemiddelfirma. Santens virksomhet består av reseptbelagte øyelegemidler, reseptfrie øyebehandlinger og medisinske hjelpemidler samt kosttilskudd for øyehelse. I Europa er vi ledende innen behandling av grønn stær og tørt øye-sykdom – områder der porteføljen vår dekker alle stadier og typer av sykdommer. Vi er også i ferd med å utvide sortimentet når det gjelder øyeinfeksjoner, allergier og utstyr for synskorrigering og kirurgi.
Development Manager Radiopharmaceuticals
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change. For more information see www.bayer.no
Radiopharmaceuticals Development Platform Lead
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change. For more information see www.bayer.no
Scientist Radiopharmaceuticals
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
Vice President Research & Development
Amicoat AS is a Norwegian biotechnology company that discovers, develops, and commercializes novel antimicrobial science with broad applications across diverse industries. Our current focus is on medical equipment, and we are also exploring utilization of our technology in other industries. With our origins above the Arctic Circle in the city of Tromsø in Northern Norway, we aspire to be a leading company in the antimicrobial coating industry, providing our clients with tailored antimicrobial coating solutions. Our primary product, AMC-109, offers a reliable and environmentally safe antimicrobial solution addressing needs across a wide range of industries. AMC-109 is backed by extensive data demonstrating efficacy and safety, and inducing antimicrobial activity with minimal environmental impact. Efficacy has also been demonstrated with viruses and fungi.
Brand Manager – Boehringer Ingelheim
Hos Boehringer Ingelheim skaper vi verdi gjennom innovasjon med ett klart mål: å forbedre livene til pasientene. Vi forsker på og utvikler banebrytende og innovative løsninger innen områder med uoppfylt medisinsk behov for både mennesker og dyr. Som et familieeid selskap har vi et langsiktig fokus. Vi kan oppsummere målene og ideene i Boehringer Ingelheim med én setning: Verdi gjennom nyskapning. Vi er over 50.000 ansatte globalt og har en kultur som preges av mangfold, samarbeid og inkluderende arbeidsmiljø. Vi drives av kontinuerlig læring og utvikling for alle ansatte, fordi din vekst er vår vekst. I Norge holder vi til i Asker og sysselsetter 65 kompetente medarbeidere.
Product Design and Development Lead
We are a stealth early stage biotech with multiple locations, including Oslo, Basel, and soon Cambridge (USA) - the name will change shortly! Our mission is to develop therapeutics that extend patients' lives and also improve their quality of life. We specialize in developing targeted radioligand therapeutics and we are growing our new company with roots in the Oslo ecosystem of radiobiology, and founders with a track record of developing new therapies. We are backed by international venture capital groups with deep scientific roots who understand what it takes to develop and scale a technology to deliver new therapies.
NorthSea Therapeutics is seeking CMC Manager
NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. NST licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS, who developed Lovaza® (US brand, branded Omacor® in Europe), a blockbuster cardiovascular drug. Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA-1024 is in phase 1 to be developed for dyslipidemia, and SEFA-6179, entered phase 1 in December 2021, is being developed for the orphan indication IFALD, (Intestinal Failure Associated Liver Disease). NST is headquartered in the Netherlands with a presence in Norway and the US and is supported by Ysios Capital, Forbion Growth, Hercules Capital, Forbion Ventures, Novo Seeds, BGV, NSV, venBio Partners and Sofinnova investments. Find out more about us online at: www.northseatherapeutics.com